newsfilter
← Latest News
GlobeNewswire·

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

  • Onconetix's Swiss subsidiary, Proteomedix AG, appointed co-founder Ralph Schiess, PhD, to its Board of Directors.
  • The appointment was approved at the Proteomedix Annual General Meeting held on June 22, 2026.
  • Thomas Meier, PhD, was re-elected as Chairman of the Proteomedix Board for an additional one-year term.
  • Dr. Schiess is the co-developer of Proclarix®, a CE-IVD certified prostate cancer diagnostic blood test originally developed at ETH Zürich.
  • Dr. Schiess brings over a decade of experience in academic institutions & over 10 years in the diagnostic industry.
  • He currently serves as the founding CEO of ZH3D at the University of Zürich.
  • Proteomedix was acquired by Onconetix in December 2023.
  • Beat Rheiner, PhD, CEO of Proteomedix AG, cited Dr. Schiess's unmatched scientific & commercial knowledge as a key value to the Board.
  • Proclarix® is approved for sale in the European Union under IVDR & Onconetix anticipates marketing it in the U.S. as a lab-developed test via a license agreement with Labcorp.
  • Onconetix is a commercial-stage biotechnology company listed on NASDAQ under the ticker ONCO.